We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 642.50
Bid: 641.00
Ask: 642.00
Change: 8.50 (1.34%)
Spread: 1.00 (0.156%)
Open: 625.00
High: 642.50
Low: 625.00
Prev. Close: 634.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

11 Feb 2022 07:00

RNS Number : 3566B
Tate & Lyle PLC
11 February 2022
 

11 February 2022 - Tate & Lyle PLC

 

 

TRADING STATEMENT

 

Tate & Lyle issues the following trading statement for the three months ended 31 December 2021.

 

Headlines

· Third quarter trading in line with our expectations

· Outlook for total operations (current Tate & Lyle Group) for the year ending 31 March 2022 unchanged, performance of continuing operations (new Tate & Lyle) now expected to be stronger

· Food & Beverage Solutions top-line momentum continues with revenue 19% higher

· New Products performance remains strong with revenue 54% higher

· Positive outcome from the 2022 calendar year pricing round

· Transaction to create two focused businesses on track for completion at the end of March 2022

 

Nick Hampton, Chief Executive said:

"Food & Beverage Solutions delivered another excellent quarter with double-digit revenue growth across all regions and continued high demand for New Products from our innovation pipeline.

 

We enter 2022 in a strong position. Our new business pipeline in Food & Beverage Solutions is healthy and in both our businesses we have renewed 2022 calendar year customer contracts that offset inflation. In addition, the transaction we announced last year to create two focused businesses is progressing well and we remain on track for completion at the end of March.

 

With Tate & Lyle re-positioned as a growth-focused, global food and beverage solutions business serving faster growing markets, we see significant opportunities ahead. Consumer demand for healthier food and drink is accelerating globally and with our leading expertise in sweetening, mouthfeel and fortification, the new Tate & Lyle is well positioned to capture this growth."

 

Continuing operations (New Tate & Lyle)

Strong top-line growth building on positive momentum in the first half.

 

Three months ended 31 December 2021

Volume

Revenue1

Food & Beverage Solutions

+6%

+19%

Sucralose

+7%

+8%

Continuing operations

+18% 

 

1 Growth in constant currency

 

Food & Beverage Solutions

Food & Beverage Solutions revenue growth continued to be strong, increasing by 19% from higher volume, price mix, the benefit of acquisitions and excellent growth from New Products. Looking through the impact of the Covid-19 pandemic and before the impact of reporting changes, compared to the quarter to 31 December 2019, volume was 12% higher and revenue 31% higher.

 

North America and Europe each delivered double-digit revenue growth reflecting good commercial performance and mix management. In Asia, Middle East, Africa and Latin America revenue growth accelerated strongly in the quarter helped by robust growth in China, South-East Asia and Mexico.

 

Sucralose

Revenue was 8% higher reflecting good customer mix and solid demand.

 

Discontinued operations1 (NewCo)

Bulk sweetener volume was broadly in line and industrial starch volume slightly lower than the comparative period. However, as expected, overall performance was significantly weaker due to cost inflation and actions taken to reduce costs in the comparative period to mitigate the impact of the global pandemic.

 

Transaction update

We remain on course to complete the sale of a controlling stake in our Primary Products business in the Americas at the end of March 2022.

 

As previously announced, following completion we intend to return approximately £500 million to ordinary shareholders by way of a special dividend with an associated share consolidation, subject to shareholder approval. We expect to announce the timing of this shortly after completion.

 

Tate & Lyle's results for the year ended 31 March 2022 will be announced on Thursday 9 June 2022.

 

Outlook for year ending 31 March 2022

The outlook for the financial year for total operations (current Tate & Lyle) remains unchanged with the performance of continuing operations expected to be stronger and discontinued operations weaker, as set out below.

 

Continuing operations (new Tate & Lyle)

· Growth in adjusted profit before tax in constant currency is now expected to be in the low double-digit percent range

 

Total operations (current Tate & Lyle Group)

· Change in adjusted diluted earnings per share in constant currency to be mid single-digits percent lower due to the performance of discontinued operations and cost inflation.

 

-------------------------------------------------------------------------------

1 The discontinued business represents the disposed Primary Products business in North America and Latin America and its interests in the Almidones Mexicanos S.A de C.V and DuPont Tate & Lyle Bio-Products Company, LLC joint ventures (also referred to in this statement as NewCo).

 

END

 

A conference call will be held today at 10.00am GMT hosted by Nick Hampton, Chief Executive. Participants are requested to dial in at least 10 minutes before the start of the call. Dial in details are as follows:

 

Standard International Access: +44 (0)3305 510 202

Password: 5507290#

 

A replay of this call will be available after the end of the live call for 14 days until 24 February 2022.

Replay number: +44 (0)20 8196 1480

Replay access PIN: 5507290#

 

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

 

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2021, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin or Facebook.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKKBBOBKDABD
Date   Source Headline
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.